Cutaneous findings following COVID-19 vaccination: review of world literature and own experience.


Journal

Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037

Informations de publication

Date de publication:
Feb 2022
Historique:
received: 29 06 2021
accepted: 29 09 2021
pubmed: 19 10 2021
medline: 19 1 2022
entrez: 18 10 2021
Statut: ppublish

Résumé

There is growing evidence that not only the novel coronavirus disease (COVID-19) but also the COVID-19 vaccines can cause a variety of skin reactions. In this review article, we provide a brief overview on cutaneous findings that have been observed since the emerging mass COVID-19 vaccination campaigns all over the world. Unspecific injection-site reactions very early occurring after the vaccination are most frequent. Type I hypersensitivity reactions (e.g. urticaria, angio-oedema and anaphylaxis) likely due to allergy to ingredients may rarely occur but can be severe. Type IV hypersensitivity reactions may be observed, including delayed large local skin lesions ("COVID arm"), inflammatory reactions in dermal filler or previous radiation sites or even old BCG scars, and more commonly morbilliform and erythema multiforme-like rashes. Autoimmune-mediated skin findings after COVID-19 vaccination include leucocytoclastic vasculitis, lupus erythematosus and immune thrombocytopenia. Functional angiopathies (chilblain-like lesions, erythromelalgia) may also be observed. Pityriasis rosea-like rashes and reactivation of herpes zoster have also been reported after COVID-19 vaccination. In conclusion, there are numerous cutaneous reaction patterns that may occur following COVID-19 vaccination, whereby many of these skin findings are of immunological/autoimmunological nature. Importantly, molecular mimicry exists between SARS-CoV-2 (e.g. the spike-protein sequences used to design the vaccines) and human components and may thus explain some COVID-19 pathologies as well as adverse skin reactions to COVID-19 vaccinations.

Identifiants

pubmed: 34661927
doi: 10.1111/jdv.17744
pmc: PMC8656409
doi:

Substances chimiques

COVID-19 Vaccines 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

172-180

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2021 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.

Références

Dermatol Online J. 2021 Jan 15;27(1):
pubmed: 33560802
JAAD Case Rep. 2021 Jul;13:134-137
pubmed: 34056055
Virus Res. 2021 Aug;301:198454
pubmed: 34015363
Ital J Dermatol Venerol. 2021 Apr;156(2):115-117
pubmed: 33960747
J Eur Acad Dermatol Venereol. 2021 Mar;35(3):e187-e189
pubmed: 33002210
J Eur Acad Dermatol Venereol. 2021 Aug;35(8):e483-e485
pubmed: 33834563
Int J Dermatol. 2021 Sep;60(9):1150-1151
pubmed: 34110010
Vaccine. 2021 Jun 8;39(25):3329-3332
pubmed: 34006408
Eur J Hosp Pharm. 2021 May 24;:
pubmed: 34031153
Dermatol Ther. 2021 Jul;34(4):e15017
pubmed: 34075664
Am J Hematol. 2021 May 1;96(5):534-537
pubmed: 33606296
ACS Cent Sci. 2021 Apr 28;7(4):512-533
pubmed: 34056083
Front Med (Lausanne). 2021 May 14;8:664179
pubmed: 34055838
J Clin Endocrinol Metab. 2021 Aug 18;106(9):2600-2605
pubmed: 34043800
Int J Radiat Oncol Biol Phys. 2021 Jul 15;110(4):957-961
pubmed: 33677050
J Cosmet Dermatol. 2021 Jun;20(6):1566-1567
pubmed: 33638924
J Eur Acad Dermatol Venereol. 2021 Sep;35(9):e548-e551
pubmed: 34021625
J Eur Acad Dermatol Venereol. 2021 Oct;35(10):e620-e622
pubmed: 34058038
J Autoimmun. 2021 Jul;121:102662
pubmed: 34051613
J Am Acad Dermatol. 2021 Jul;85(1):46-55
pubmed: 33838206
J Eur Acad Dermatol Venereol. 2021 Sep;35(9):e543-e545
pubmed: 34048614
J Allergy Clin Immunol. 2021 Jun;147(6):2075-2082.e2
pubmed: 33857566
Am J Hematol. 2021 May 1;96(5):E133-E134
pubmed: 33476455
J Thromb Haemost. 2021 Jun;19(6):1515-1518
pubmed: 33783953
J Blood Med. 2021 Apr 06;12:221-224
pubmed: 33854395
Cureus. 2021 Apr 5;13(4):e14303
pubmed: 33968515
Dermatol Ther. 2020 Sep;33(5):e13549
pubmed: 32390279
Ann Emerg Med. 2021 Jun;77(6):654-656
pubmed: 34030782
J Eur Acad Dermatol Venereol. 2021 Oct;35(10):e645-e647
pubmed: 34169578
JAMA Dermatol. 2020 Sep 1;156(9):998-1003
pubmed: 32584377
J Cosmet Dermatol. 2021 Nov;20(11):3389-3390
pubmed: 34077622
JAMA Dermatol. 2021 Jun 1;157(6):716-720
pubmed: 33978670
Br J Haematol. 2021 Aug;194(3):547-549
pubmed: 33934330
Clin Immunol. 2021 Jun;227:108748
pubmed: 33932618
Biology (Basel). 2020 Dec 05;9(12):
pubmed: 33291502
Clin Immunol. 2021 May;226:108721
pubmed: 33823270
Pharmacol Res. 2015 Oct;100:190-209
pubmed: 26275795
Hematology. 2021 Dec;26(1):225-239
pubmed: 33594951
JAAD Case Rep. 2021 Jun;12:12-14
pubmed: 33898675
J Eur Acad Dermatol Venereol. 2021 Apr;35(4):e246-e247
pubmed: 33258224
JAAD Case Rep. 2021 Apr;10:63-68
pubmed: 33681439
Clin Exp Dermatol. 2021 Oct;46(7):1325-1327
pubmed: 33914926
Curr Opin Virol. 2021 Aug;49:52-57
pubmed: 34049261
Cureus. 2021 Apr 13;13(4):e14453
pubmed: 33996313
J Eur Acad Dermatol Venereol. 2021 Jul;35(7):e415-e416
pubmed: 33725406
Anatol J Cardiol. 2020 Oct;24(4):224-234
pubmed: 33001051
J Eur Acad Dermatol Venereol. 2021 Oct;35(10):e626-e627
pubmed: 34077572
Dermatitis. 2021 May-Jun 01;32(3):133-139
pubmed: 33851937
Dermatol Clin. 2021 Oct;39(4):653-673
pubmed: 34556254
J Cosmet Dermatol. 2021 Jul;20(7):1965-1966
pubmed: 33969620
J Clin Med Res. 2021 Apr;13(4):204-213
pubmed: 34007358
Rheumatology (Oxford). 2021 Oct 9;60(SI):SI90-SI95
pubmed: 33848321
J Med Virol. 2021 Apr;93(4):1850-1851
pubmed: 32970319
Vaccines (Basel). 2021 May 06;9(5):
pubmed: 34066475
JAAD Case Rep. 2021 Jun;12:58-59
pubmed: 33937467
Int J Dermatol. 2021 Aug;60(8):1032-1033
pubmed: 33928638
Clin Dermatol. 2021 Jul-Aug;39(4):674-687
pubmed: 34809772
JAAD Int. 2021 Mar;2:119-133
pubmed: 33479703
Med Clin (Barc). 2021 Nov 26;157(10):e333-e334
pubmed: 34119340
Front Immunol. 2021 Apr 15;12:656362
pubmed: 33936084
J Eur Acad Dermatol Venereol. 2021 Jul;35(7):e423-e425
pubmed: 33783017
Hum Vaccin Immunother. 2021 Sep 2;17(9):2954-2956
pubmed: 34033732
Clin Exp Dermatol. 2021 Aug;46(6):1131-1134
pubmed: 33835617
J Am Acad Dermatol. 2021 May;84(5):1251
pubmed: 33775460
Clin Dermatol. 2021 May-Jun;39(3):523-531
pubmed: 34518015
Thyroid. 2021 Sep;31(9):1436-1439
pubmed: 33858208
J Eur Acad Dermatol Venereol. 2021 Jul;35(7):e425-e427
pubmed: 33783873

Auteurs

T Gambichler (T)

Department of Dermatology, Ruhr-University Bochum, Bochum, Germany.
Department of Dermatology, Christian Hospital Unna, Unna, Germany.

S Boms (S)

Department of Dermatology, Christian Hospital Unna, Unna, Germany.

L Susok (L)

Department of Dermatology, Ruhr-University Bochum, Bochum, Germany.

H Dickel (H)

Department of Dermatology, Ruhr-University Bochum, Bochum, Germany.

C Finis (C)

Department of Dermatology, Ruhr-University Bochum, Bochum, Germany.

N Abu Rached (N)

Department of Dermatology, Ruhr-University Bochum, Bochum, Germany.

M Barras (M)

Department of Dermatology, Ruhr-University Bochum, Bochum, Germany.

M Stücker (M)

Department of Dermatology, Ruhr-University Bochum, Bochum, Germany.

D Kasakovski (D)

European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Division of Vascular Oncology and Metastasis, German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH